2022
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
John BV, Deng Y, Schwartz KB, Taddei TH, Kaplan DE, Martin P, Chao H, Dahman B. Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology 2022, 76: 126-138. PMID: 35023206, PMCID: PMC9015228, DOI: 10.1002/hep.32337.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19Breakthrough COVID-19 infectionsBreakthrough COVID-19Propensity-matched cohortRetrospective cohort studyCOVID-19 patientsPfizer BNT162b2Unvaccinated participantsFull vaccinationCohort studyFirst dosePartial vaccinationMultivariable analysisSecond doseUS veteransCirrhosisReduced riskVaccine availabilityPatientsVaccinationVaccineInfectionMortalityDose
2021
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis
John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, Labrada M, Baracco G, Dahman B. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine 2021, 181: 1306-1314. PMID: 34254978, PMCID: PMC8278308, DOI: 10.1001/jamainternmed.2021.4325.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19-related hospitalizationBNT162b2 mRNAFirst doseCohort studySecond doseMRNA vaccinesClinical trialsControl groupPropensity-matched control groupPhase 3 clinical trialsCOVID-19 mRNA vaccinesAssociation of vaccinationRetrospective cohort studyUS veteran populationAssociation of receiptVeterans Health AdministrationCoronavirus disease 2019COVID-19 hospitalizationMRNA vaccine administrationCOVID-19Vaccine recipientsImmune dysregulationModerna mRNAMedian age
2017
Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.
Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.Peer-Reviewed Original ResearchDuration of exposureBCLC BICD9 codesBarcelona Clinic Liver Cancer stageInitiation of sorafenibMedian overall survivalLiver Cancer stageLonger exposure durationECOG PSExposure durationUp-titrationChild-TurcotteMELD scoreSorafenib therapyFirst doseOverall survivalPharmacy recordsMedian agePrescription fillsLiver diseaseTumor numberC-HCCEquivalent survivalHCC patientsCancer stage